Tamtam Try Tamtam free
BeOne Medicines logo

BeOne Medicines account plan

global oncology drug development

At a glance

BeOne Medicines (formerly BeiGene) is a global oncology company behind BRUKINSA: FY2025 revenue $5.3 billion, nearly 12,000 employees.

BeOne Medicines, formerly BeiGene, is a global oncology company that discovers, develops, manufactures and sells cancer medicines, led by the BTK inhibitor BRUKINSA and the anti-PD-1 antibody TEVIMBRA, plus in-licensed products sold mainly in China. Founded in 2010, it redomiciled to Switzerland (registered office in Basel) in 2025, operates through subsidiaries in the U.S., China, the UK and Australia, and is listed on Nasdaq, HKEx and the Shanghai STAR board. FY2025 total revenue was $5,343.0 million (+40.2%), with net income of $286.9 million, its first year of GAAP profit, and free cash flow of $941.7 million; the U.S. contributed $2,880.3 million and China $1,679.5 million. It had nearly 12,000 full-time employees as of February 13, 2026, about 1,900 of them in the U.S.

Business units

Strategic priorities

Lead in CLL with three mechanisms
Build a hematology franchise on BRUKINSA, BEQALZI and tacabrutideg, targeting leadership in the approximately $12 billion global CLL market, with registrational programs in treatment-naive and relapsed settings.
Expand BRUKINSA into 1L mantle cell lymphoma
The MANGROVE filing (BRUKINSA plus rituximab) has FDA Priority Review and was submitted in the EU and China, with a Japan submission in Q4 2026.
Make 2026 a solid tumor inflection year
Five solid tumor programs reached proof of concept, with Phase 3 starts in HCC in Q4 2026 and 1H 2027, a B7-H4 ADC Phase 3 in ovarian cancer and a CDK4 Phase 3 upsized to 1,200 patients.
Grow TEVIMBRA globally
Expand TEVIMBRA's footprint and build global commercial capabilities, with China decisions on TEVIMBRA and ZIIHERA in 1L HER2+ GEA expected in 1H 2027.
Disciplined growth with measured margin expansion
Raised FY2026 guidance to $6.9-7.0 billion revenue and $1.2-1.3 billion GAAP operating income; the CFO expects margin expansion in 2027 to be modest as operating expenses keep growing.

Latest results

In Q3 2026 total revenue rose 33.8% to $1,889.8 million, with BRUKINSA up 33.7% to $1,390.9 million and TEVIMBRA up 27.6% to $243.3 million. Income from operations grew 156.7% to $418.7 million and net income 208.2% to $384.7 million, while free cash flow was $473.5 million; the gross margin on product sales reached 88.3%. Nine-month revenue was $5,108.3 million (+32.9%). BeOne raised its FY2026 guidance to total revenue of $6.9-7.0 billion and expects a tax valuation allowance reversal in Q4 2026.

Investments and deals

Hopewell, New Jersey expansion
A $300 million expansion of the Hopewell biologics site was announced in 2026, adding to a 42-acre site with 8,000 liters of capacity opened in July 2024.
Revolution Medicines collaboration
Signed August 10, 2026: combination trials with its four clinical RAS(ON) inhibitors and exclusive rights to those assets in select Asian markets.
R&D spending
R&D was $2,145.9 million in 2025 and rose 26.2% to $660.8 million in Q3 2026 as programs moved to late stage; an in-house clinical team of about 3,800 people runs trials largely without CROs.
Royalty and debt financing
Royalty Pharma paid $885 million upfront for IMDELLTRA royalties, and a November 2025 HSBC-led Facilities Agreement refinanced about $768 million of short-term loans.
U.S. access and manufacturing agreement
A voluntary agreement with the U.S. government on August 31, 2026 to expand access to cancer medicines and strengthen the U.S. manufacturing footprint.

Challenges and risks

Competition in BTK and PD-1 classes
BRUKINSA competes with acalabrutinib, ibrutinib and pirtobrutinib, and TEVIMBRA faces steep competition in China; CELESTIAL-301 missed uMRD superiority versus VO.
Pricing and reimbursement pressure
The U.S. Inflation Reduction Act, a Medicare Part D liability increase expected to be a flat to modest headwind in 2027, and China's NRDL and volume-based procurement.
In-licensed product erosion in China
XGEVA biosimilars and potential VBP inclusion for XGEVA and KYPROLIS will likely pressure revenue beyond 2026.
U.S.-China relations
PRC government policy, U.S.-China relations and CSRC filing requirements are named risks for a company with large operations in both countries.
Dependence on distributors and CMOs
Cencora (18.5%), McKesson (17.5%) and Shanghai Pharmaceutical (10.1%) accounted for large shares of 2025 product revenue, and BeOne relies on contract manufacturers.

What leadership says

“Across every dimension of the business, BeOne is executing at the very highest level in our history.”

John V. Oyler, Co-Founder, Chairman and CEO · Q3 2026 earnings call (November 5, 2026)

“we are living up to our promise that 2026 would be an inflection year”

John V. Oyler, Co-Founder, Chairman and CEO · Q3 2026 earnings call (November 5, 2026), on the solid tumor pipeline

“the pace of margin expansion is likely to be modest as compared to 2025 and 2026”

Aaron Rosenberg, CFO · Q3 2026 earnings call (November 5, 2026)

“building disease franchises rather than stand-alone products”

Lai Wang, President and Global Head of R&D · Q2 2026 earnings call (August 5, 2026)

Where a supplier can help

Late-stage trial supplies and services
Tied to the solid tumor Phase 3 starts and the in-house clinical organization: lab reagents, consumables, toxicology and trial logistics for a team running trials largely without CROs.
Biologics manufacturing equipment
Tied to the $300 million Hopewell expansion and the U.S. manufacturing agreement: process equipment, automation and validation services.
Commercial launch support
Tied to BEQALZI, MANGROVE in 1L MCL and TEVIMBRA's global expansion: market access, medical affairs and commercial data services in the U.S., Europe, Japan and Brazil.
Pricing and reimbursement analytics
Tied to IRA, Medicare Part D and China VBP pressures: health economics, contracting and gross-to-net tools.
Supply chain resilience
Tied to the dependence on CMOs and on three distributors: supplier-risk, dual-sourcing and distribution analytics offers.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like BeOne Medicines?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about BeOne Medicines

What does BeOne Medicines do?

BeOne Medicines, formerly BeiGene, is a global oncology company. Its main medicines are BRUKINSA for B-cell cancers and TEVIMBRA, an anti-PD-1 antibody, and it sells Amgen and other partners' products in China.

What is BeOne Medicines' revenue?

FY2025 total revenue was $5,343.0 million, up 40.2%. The company guides to $6.9-7.0 billion for 2026.

How many employees does BeOne Medicines have?

Nearly 12,000 full-time employees as of February 13, 2026, about 1,900 in the U.S.

Who leads BeOne Medicines?

John V. Oyler is Co-Founder, Chairman and CEO; Xiaobin Wu is President and COO and Aaron Rosenberg is CFO.

What is BeOne Medicines' strategy?

It aims to lead CLL with three mechanisms (BRUKINSA, BEQALZI, tacabrutideg), expand TEVIMBRA globally and build solid tumor franchises in breast, lung and gastrointestinal cancers.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)